Literature DB >> 2292139

Vascular attack as a therapeutic strategy for cancer.

J Denekamp1.   

Abstract

The blood supply to all solid tumours consists of parasitized normal vessels and new vessels which have been induced to grow by the presence of the tumour. These vessels are inadequate in many respects, being tortuous, thin-walled, chaotically arranged, lacking innervation and with no predetermined direction of flow. The walls consist of a basement membrane lined with rapidly proliferating immature endothelial cells, and are more permeable than normal vessels. The spacing of the vessels and their average diameters are not optimal for nutrient provision. This paper focuses on the evidence that many existing therapies may already have, as part of their action, a vascular mediated process of killing tumour cells. This may result from local changes within individual vessels or from systemic alterations in blood pressure, viscosity, coagulability etc. The hallmarks of vascular injury are identified and the dangers of discarding useful anticancer agent by failing to understand their mechanism of action are highlighted.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2292139     DOI: 10.1007/bf00046365

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  69 in total

1.  Selective chemotherapy of noncycling cells in an in vitro tumor model.

Authors:  R M Sutherland
Journal:  Cancer Res       Date:  1974-12       Impact factor: 12.701

2.  Blood flow and intravascular volume of mammary adenocarcinoma 13726A and normal tissues of rat during and following hyperthermia.

Authors:  D S Rappaport; C W Song
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-04       Impact factor: 7.038

3.  Vascular occlusion and tumour cell death.

Authors:  J Denekamp; S A Hill; B Hobson
Journal:  Eur J Cancer Clin Oncol       Date:  1983-02

4.  Endotoxin-mediated necrosis and regression of established tumours in the mouse. A correlative study of quantitative changes in blood flow and ultrastructural morphology.

Authors:  G G MacPherson; R J North
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  Modification of stromal radiosensitivity by misonidazole and WR-2721.

Authors:  A C Begg; N H Terry
Journal:  Br J Radiol       Date:  1983-08       Impact factor: 3.039

6.  Flavone acetic acid induces a coagulopathy in mice.

Authors:  J C Murray; K A Smith; G Thurston
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

7.  The gross response of an experimental tumour to single doses of x-rays.

Authors:  R H Thomlinson; E A Craddock
Journal:  Br J Cancer       Date:  1967-03       Impact factor: 7.640

8.  Factors influencing the chemosensitization of melphalan by misonidazole.

Authors:  V S Randhawa; F A Stewart; J Denekamp; M R Stratford
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

9.  Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells.

Authors:  M P Bevilacqua; J S Pober; G R Majeau; R S Cotran; M A Gimbrone
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

10.  The effects of melphalan and misonidazole on the vasculature of a murine sarcoma.

Authors:  J C Murray; V Randhawa; J Denekamp
Journal:  Br J Cancer       Date:  1987-03       Impact factor: 7.640

View more
  42 in total

Review 1.  Vascular targeting agents.

Authors:  Mary Jo Pilat; Julie McCormick; Patricia Mucci LoRusso
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

Review 2.  Drug carrier interaction with blood: a critical aspect for high-efficient vascular-targeted drug delivery systems.

Authors:  Daniel J Sobczynski; Margaret B Fish; Catherine A Fromen; Mariana Carasco-Teja; Rhima M Coleman; Omolola Eniola-Adefeso
Journal:  Ther Deliv       Date:  2015-08-14

Review 3.  Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction.

Authors:  J Folkman
Journal:  Cancer Metastasis Rev       Date:  1990-11       Impact factor: 9.264

4.  Anti-angiogenesis as a new concept for the therapy of neovascular diseases.

Authors:  L Schweigerer
Journal:  Klin Wochenschr       Date:  1991-07-22

Review 5.  Tumor vascular infarction: prospects and challenges.

Authors:  Rana Jahanban-Esfahlan; Khaled Seidi; Nosratollah Zarghami
Journal:  Int J Hematol       Date:  2017-01-02       Impact factor: 2.490

6.  Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration.

Authors:  Harriet C Thoeny; Frederik De Keyzer; Feng Chen; Vincent Vandecaveye; Erik K Verbeken; Bisan Ahmed; Xihe Sun; Yicheng Ni; Hilde Bosmans; Robert Hermans; Allan van Oosterom; Guy Marchal; Willy Landuyt
Journal:  Neoplasia       Date:  2005-08       Impact factor: 5.715

7.  A ribonuclease inhibitor expresses anti-angiogenic properties and leads to reduced tumor growth in mice.

Authors:  I J Polakowski; M K Lewis; V R Muthukkaruppan; B Erdman; L Kubai; R Auerbach
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

8.  Genistein, a dietary-derived inhibitor of in vitro angiogenesis.

Authors:  T Fotsis; M Pepper; H Adlercreutz; G Fleischmann; T Hase; R Montesano; L Schweigerer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

9.  Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature.

Authors:  F J Burrows; P E Thorpe
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

10.  A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapy.

Authors:  Bei Chen; Shanshan Cao; Yingqi Zhang; Xin Wang; Jie Liu; Xiaoli Hui; Yi Wan; Wenqi Du; Li Wang; Kaichun Wu; Daiming Fan
Journal:  BMC Cell Biol       Date:  2009-09-09       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.